Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Clinical Trials

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...

Hazard Ratio

Hazard Ratio

The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Rare disease genomics and justice: overview of a workshop at the Fondation Brocher, 22-24 January 2025.

Journal of community genetics·2026

Same author

TrialR: critical enablers and the need for reusable Rare Disease Clinical Trial infrastructure in Western Australia.

Orphanet journal of rare diseases·2026

Same author

Translating multi-omics into healthcare: requisites for scalable and equitable implementation.

Human genomics·2026

Same author

Challenges and opportunities for the use of telehealth in rare disease diagnosis, treatment, research, and education: key opinion leader interviews by the IRDiRC telehealth task force.

Therapeutic advances in rare disease·2026

Same author

Plasma lipidomics, choline metabolites, and metabolic-associated steatotic liver disease (MASLD): A Coronary Artery Risk Development in Young Adults (CARDIA) study.

PloS one·2026

Same author

Fostering equity in precision health through diverse 3D facial data.

Frontiers in medical technology·2026

Search research articles

Related Experiment Video

Updated: Jun 21, 2025

A Novel Method for Involving Women of Color at High Risk for Preterm Birth in Research Priority Setting

A Novel Method for Involving Women of Color at High Risk for Preterm Birth in Research Priority Setting

Published on: January 12, 2018

Increasing Diversity, Equity, Inclusion, and Accessibility in Rare Disease Clinical Trials.

Gareth Baynam¹, Simeón Baker^2,3,4, Charles Steward^2,3

¹Rare Care Centre, Perth Children's Hospital, Perth, WA, Australia.

Pharmaceutical Medicine

|July 8, 2024

Summary

Integrating diversity, equity, inclusion, and accessibility (DEIA) into rare diseases clinical research is crucial for success. Proactive DEIA strategies, focusing on genetic diversity, enhance trial generalizability and benefit all populations.

More Related Videos

Involving Individuals with Developmental Language Disorder and Their Parents/Carers in Research Priority Setting

Involving Individuals with Developmental Language Disorder and Their Parents/Carers in Research Priority Setting

Published on: June 6, 2020

In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila

In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila

Published on: August 20, 2019

Related Experiment Videos

Last Updated: Jun 21, 2025

A Novel Method for Involving Women of Color at High Risk for Preterm Birth in Research Priority Setting

A Novel Method for Involving Women of Color at High Risk for Preterm Birth in Research Priority Setting

Published on: January 12, 2018

Involving Individuals with Developmental Language Disorder and Their Parents/Carers in Research Priority Setting

Involving Individuals with Developmental Language Disorder and Their Parents/Carers in Research Priority Setting

Published on: June 6, 2020

In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila

In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila

Published on: August 20, 2019

Area of Science:

Clinical Research
Rare Diseases
Health Equity

Background:

Diversity, Equity, Inclusion, and Accessibility (DEIA) are fundamental to medical research.
In rare diseases research, participant numbers are limited, making inclusion vital for trial success and result generalizability.
Existing DEIA literature for rare diseases is growing, with increasing focus on genetic diversity.

Purpose of the Study:

To review and provide insights on proactively integrating DEIA into rare diseases clinical research.
To highlight the importance of genetic diversity within DEIA frameworks for rare diseases.
To identify successful case studies and strategies for enhancing DEIA in rare diseases research.

Main Methods:

Comprehensive review of medical and gray literature.
Analysis of case examples demonstrating DEIA integration.
Focus on strategies for incorporating genetic diversity.

Main Results:

DEIA principles are increasingly being adopted in rare diseases research.
Patient advocacy groups, professional societies, and funders are developing intentional DEIA strategies and metrics.
Successful examples exist for engaging underserved and underrepresented populations.

Conclusions:

Proactive DEIA integration is essential for rare diseases clinical research success.
Genetic diversity is a key component of DEIA in this field.
Leveraging successful case studies can guide future DEIA initiatives, ultimately benefiting all populations through diverse data insights.